TPST
Tempest Therapeutics enters licensing pact
Exclusive collaboration agreement with Hebei Senlang for a drug candidate license, aiming to develop therapeutic products.
TPST news
Latest 2 stories · newest Sep 17, 2026
TPST
Tempest Therapeutics Appoints Drake Richey and John Yee to Board
Tempest Therapeutics appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its Board of Directors effective June 4, 2026. The appointments bring financial advisory and therapeutic product development expertise as the company advances its CAR-T cell therapy pipeline for cancer t…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same TPST feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/TPST/newsSTART FREE